WebNews

Please enter a web search for web results.

NewsWeb

Cantech Letter
cantechletter.com > 2025 > 11 > this-canadian-biotech-stock-is-looking-to-treat-spinal-cord-injuries

This Canadian biotech stock is looking to treat spinal cord injuries

This Canadian biotech stock is looking to treat spinal cord injuries1+ mon, 2+ week ago   (310+ words) In a Nov. 24 update, Research Capital analyst Andr" Uddin maintained his "Speculative Buy" rating and $7.70 target price on NervGen Pharma (NervGen Pharma Stock Quote, Chart, News, Analysts, Financials TSXV:NGEN), which is developing NVG-291 for the treatment of spinal cord…...